#104, Decoding the Immune System with AI, Adam Laing from IMU Biosciences

AWS Health Innovation Podcast

Player FM - Internet Radio Done Right

اضافه شده در three سال پیش

محتوای ارائه شده توسط AWS Startups. تمام محتوای پادکست شامل قسمت‌ها، گرافیک‌ها و توضیحات پادکست مستقیماً توسط AWS Startups یا شریک پلتفرم پادکست آن‌ها آپلود و ارائه می‌شوند. اگر فکر می‌کنید شخصی بدون اجازه شما از اثر دارای حق نسخه‌برداری شما استفاده می‌کند، می‌توانید روندی که در اینجا شرح داده شده است را دنبال کنید.https://fa.player.fm/legal

Silver Linings with The Old Gays

1
Our Chosen Family: "The gay community is much bolder today." 33:19

17 روز پیش33:19

پخش در آینده

لیست ها

پسندیدن

دوست داشته شد

33:19

What’s the secret to lasting friendships? How does queer community show up through the ebbs and flows of life? And what’s the REAL story behind the “YMCA” song? In the first episode of Silver Linings, The Old Gays dive into an essential part of queer life: chosen family. They discuss the vital love, support, and sense of belonging that community provides, especially during life's toughest moments. They open up about what “queer” means to them, how chosen family has impacted their lives, and how to maintain close bonds over time–including their love for each other! “We’ve come a long way, baby.” Family isn’t just what you’re born with; it’s the people who show up, shape you, and stick around. See omnystudio.com/listener for privacy information.…

حدود یک سال پیش 29:45

MP3•خانه قسمت

1. How is IMU Biosciences unlocking immune insights?

IMU Biosciences' pioneering technology measures 80 million data points across 2,000 immune cell subsets, from a small blood sample, providing unprecedented resolution into an individual's immune profile. This enables precision medicine approaches across disease areas like cancer, autoimmunity, and cell therapy.

2. What is the potential of predictive immune profiling?

By deeply characterizing immune systems, IMU aims to predict disease progression and treatment responses. Their machine learning analytics identify immune signatures that can stratify patients based on how effectively they will respond to therapies.

3. How does IMU Biosciences foster a collaborative culture?

With a team spanning immunology, data science, engineering, and operations, IMU fosters a collaborative culture focused on solving complex problems. Their network and reputation helped secure early industry partnerships.

4. What is IMU Biosciences' vision for scaling precision immunology?

After demonstrating their technology's potential during COVID-19 research, IMU raised a Series A to commercialize and build a predictive immune data platform. Their long-term vision is enabling preventative screening for disease risk.

5. How does IMU Biosciences leverage advances in flow cytometry?

IMU leverages advances in flow cytometry instrumentation, labeling 75 markers to phenotype cells at unprecedented resolution. Robust processes ensure scalability by accounting for technical variability across samples.

Learn more about IMU Biosciences here to explore their pioneering work in unlocking the complexity of the immune system and advancing precision medicine.

Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.

Please take a moment and let us know what you think of the podcast, access our feedback survey here.

131 قسمت

#Tech #Joe Shonkwiler

AWS Health Innovation Podcast

#104, Decoding the Immune System with AI, Adam Laing from IMU Biosciences

AWS Health Innovation Podcast

published حدود یک سال پیش

اشتراک گذاری

MP3•خانه قسمت

1. How is IMU Biosciences unlocking immune insights?

IMU Biosciences' pioneering technology measures 80 million data points across 2,000 immune cell subsets, from a small blood sample, providing unprecedented resolution into an individual's immune profile. This enables precision medicine approaches across disease areas like cancer, autoimmunity, and cell therapy.

2. What is the potential of predictive immune profiling?

By deeply characterizing immune systems, IMU aims to predict disease progression and treatment responses. Their machine learning analytics identify immune signatures that can stratify patients based on how effectively they will respond to therapies.

3. How does IMU Biosciences foster a collaborative culture?

With a team spanning immunology, data science, engineering, and operations, IMU fosters a collaborative culture focused on solving complex problems. Their network and reputation helped secure early industry partnerships.

4. What is IMU Biosciences' vision for scaling precision immunology?

After demonstrating their technology's potential during COVID-19 research, IMU raised a Series A to commercialize and build a predictive immune data platform. Their long-term vision is enabling preventative screening for disease risk.

5. How does IMU Biosciences leverage advances in flow cytometry?

IMU leverages advances in flow cytometry instrumentation, labeling 75 markers to phenotype cells at unprecedented resolution. Robust processes ensure scalability by accounting for technical variability across samples.

Learn more about IMU Biosciences here to explore their pioneering work in unlocking the complexity of the immune system and advancing precision medicine.

Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.

Please take a moment and let us know what you think of the podcast, access our feedback survey here.

131 قسمت

#Tech #Joe Shonkwiler

همه قسمت ها

AWS Health Innovation Podcast

1
#124, From Search Algorithms to Scientific Breakthroughs with Doug Selinger from Plex Research 21:30

10 روز پیش21:30

21:30

Learn how Plex Research combines PageRank-style algorithms with AI to navigate the complexity of biomedical data, transforming untapped research potential into validated drug discovery opportunities.

AWS Health Innovation Podcast

1
#123, Decoding Immune Cell Behavior to Transform Treatment Discovery with Gregory Vladimer from Graph Therapeutics 19:45

17 روز پیش19:45

19:45

The intersection of AI and immunology is revolutionizing how we understand and treat complex immune disorders. In this episode of the AWS Health Innovation Podcast, Mike Tarselli , Specialist Leader for HCLS Data & AI, explores the future of precision immunology with Gregory Vladimer , Scientific Co-Founder & CEO of Graph Therapeutics. Graph's innovative approach combines AI-powered analysis with patient cell behavior to develop targeted therapies for millions affected by immune-mediated diseases. How does one transition from immunology research to leading a TechBio company? Gregory Vladimer's evolution from bench scientist to CEO reflects the changing landscape of drug discovery leadership, where deep scientific expertise meets technological innovation. What distinguishes TechBio 3.0 from earlier approaches? Modern TechBio companies like Graph represent a more sophisticated model, combining specialized domain knowledge with strategic tech partnerships to enhance drug discovery capabilities. How does Graph's approach to precision medicine differ? By leveraging functional perturbation modeling and multi-omics data analysis, Graph applies precision oncology principles to decode and treat complex immune conditions like rheumatoid arthritis and Crohn's disease. What role does AI play in Graph's drug discovery platform? Advanced machine learning systems analyze complex biological data across multiple endpoints, while maintaining scientific rigor through human-in-the-loop validation processes. What's the long-term vision for immune disease treatment? Graph focuses on building predictive disease models and a comprehensive target generation engine, prioritizing curative potential over rapid commercialization. Learn more about Graph Therapeutics at https://graphtx.com/ Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here.…

AWS Health Innovation Podcast

1
#122, Revolutionizing Heart Failure Care Through Non-Invasive Sensing with Filip Peters from Acorai 30:49

24 روز پیش30:49

30:49

Heart failure affects over 60 million people worldwide, yet monitoring blood pressure inside the heart remains an invasive, complex procedure. In this episode of the AWS Health Innovation Podcast, Guy Spigelman , EMEA lead for Healthcare and Life Sciences Startups at AWS, speaks with Filip Peters , CEO of Acorai, about their groundbreaking non-invasive SAVE Sensor System that combines multiple sensing technologies to measure intracardiac pressures - potentially transforming how we manage heart failure. 1. How did Filip transition from finance to healthcare technology? Drawing from his background in machine learning and financial technology, Filip identified an opportunity to apply advanced analytics to cardiac monitoring. His transition exemplifies how cross-industry expertise can drive healthcare innovation. 2. What makes the SAVE Sensor System unique? The system integrates four distinct sensor types - seismic, acoustic, visual, and electrical - creating a comprehensive approach to non-invasive cardiac monitoring. This novel combination enables detailed measurement of intracardiac pressures without invasive procedures. 3. How does Acorai's technology impact patient care? By enabling frequent, non-invasive pressure monitoring, healthcare providers can track heart failure progression more effectively. This capability supports earlier interventions and more precise treatment adjustments, potentially improving outcomes for millions of patients. 4. What considerations went into the device design? Acorai prioritized portability and user experience, creating an intuitive interface that integrates seamlessly with existing hospital workflows. This practical approach addresses key adoption barriers in clinical settings. 5. What milestones indicate Acorai's market potential? The company has expanded operations across six countries and received FDA Breakthrough Device Designation, demonstrating strong market validation and regulatory progress. These achievements reflect growing confidence in Acorai's innovative approach. Learn more about Acorai at https://acorai.com/ Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here.…

AWS Health Innovation Podcast

1
#121, Engineering Better Drugs Through Bacterial Intelligence with Nik Sharma & Mo Alomari from BioCorteX 0:13

۵ weeks پیش0:13

0:13

The complex relationship between bacteria and medication efficacy represents one of medicine's most overlooked frontiers. In this episode of the AWS Health Innovation Podcast, Amrita Sarkar, GenAI Leader for Health & Bio at AWS Startups, speaks with Nik Sharma (CEO and Co-Founder) and Muhannad Alomari (CTO and Co-Founder) of BioCorteX. Their groundbreaking work in computational drug-bacteria interaction analysis is reshaping our understanding of personalized medicine and drug development. What inspired BioCorteX's approach to pharmaceutical development? People living with diseases cannot wait. Drawing from tried and tested engineering methodology, BioCorteX applies sophisticated engineering principles to transform drug development success rates by exploring the drug-bacteria interactions. This cross-industry innovation demonstrates how established engineering practices can revolutionize pharmaceutical outcomes. What role does evolutionary biology play in BioCorteX's research methodology? The company's approach is fundamentally built on the fact that mitochondria – the power house of cells – are ex-bacteria. This deep historical connection provides crucial insights into how bacterial interactions influence medication responses across diverse populations. How does BioCorteX manage the complexity of human-bacterial interactions? Understanding biology is one of the most complex tasks that humanity has ever attempted to tackle , with human bacteria interactions that far exceeds the number of stars in our galaxy. Their proprietary Carbon Mirror technology employs advanced emulation technologies to analyze drug-bacteria relationships at an unprecedented scale. This in-silico approach enables the exploration of complex interactions that traditional laboratory methods simply cannot possibly capture. What makes BioCorteX's data approach unique in pharmaceutical development? The Carbon Knowledge platform leverages 15 million samples from 165 different geopolitical regions worldwide, enabling highly accurate drug trial outcome predictions. The scale and geographical breadth of this highly curated data help optimize clinical trials and enhance success rates for pharmaceutical companies. How does BioCorteX maintain efficiency with a lean team structure? Operating with just twelve team members, BioCorteX maintains an strong and radically transparent culture where everyone codes while partnering with major industry players. Their focus on scalable output and revenue generation challenges traditional startup growth models. What does BioCorteX's future in personalized medicine look like? The recent partnership with Tempus demonstrates BioCorteX's commitment to advancing personalized medicine. Their technology platform is positioned to fundamentally change how pharmaceutical companies approach drug development and patient care particularly when moving assets across regions i.e China to Global. Learn more about BioCorteX at https://BioCorteX.com/ Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here.…

AWS Health Innovation Podcast

1
#120, Predicting Trial Success Before Recruitment with Orr Inbar from QuantHealth 39:28

۷ weeks پیش39:28

39:28

What if you could peer into the future of a clinical trial before enrolling a single patient? In this episode of the AWS Health Innovation Podcast, Alex Merwin, Head of Growth for Healthcare & Life Science Startups at AWS, sits down with Orr Inbar, Co-Founder & CEO of QuantHealth, to explore their groundbreaking platform that's revolutionizing drug development through clinical trial simulation. Their technology is transforming how pharmaceutical companies evaluate and advance potential therapies. 1. How is QuantHealth reshaping pharmaceutical research? By leveraging an extensive database of 350 million patient records and sophisticated AI models, QuantHealth's platform achieves an impressive 86% accuracy in predicting trial outcomes. This capability directly addresses the industry's persistent challenges of rising costs and high failure rates. 2. What fundamental industry challenges does QuantHealth address? The pharmaceutical industry struggles with average development costs of $3 billion and timelines exceeding a decade. Modern precision medicine requirements have added new layers of complexity to the drug development process, making traditional approaches increasingly challenging. 3. How did QuantHealth evolve during the pandemic era? Born during COVID-19, QuantHealth developed an AI-driven solution that effectively bridges the critical gap between preclinical and clinical stages. Their platform now processes thousands of trials annually, demonstrating remarkable precision in predicting outcomes. 4. What makes QuantHealth's technical approach unique? The platform combines biological knowledge graphs with deep learning models to create digital twins of both drugs and patients. This innovative approach spans more than 50 medical indications and multiple treatment modalities, enabling comprehensive trial simulation. 5. What real-world impact has QuantHealth demonstrated? Through partnerships with major pharmaceutical companies, QuantHealth has helped increase trial success rates by 15% while simultaneously reducing development timelines. Their simulation technology has made previously unfeasible trials possible. Learn more about QuantHealth's innovative approach to clinical trial optimization at quanthealth.ai Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here.…

AWS Health Innovation Podcast

1
#119, Transforming Medical Device Development with Alex Condon from Galen Data 32:03

۸ weeks پیش32:03

32:03

From developing advanced technology for astronauts to revolutionizing medical device connectivity, every founders' innovation journey includes unexpected twists and turns. In this episode of the AWS Health Innovation Podcast, Yin He, Principal of Business Development for Healthcare & Life Sciences Startups at AWS, explores the transformative world of medical device cloud solutions with Alex Condon, COO and Co-founder of Galen Data. Their discussion reveals how Galen Data is helping medical device companies achieve FDA-compliant cloud connectivity in a fraction of the traditional time. 1. How did the transition from NASA contracting to medical devices shape Galen Data's vision? Alex's experience in NASA contracting revealed striking parallels between spaceflight and medical device compliance requirements. This unique perspective helped shape Galen Data's approach to creating simplified, yet robust cloud infrastructure specifically for healthcare technology. 2. What key challenges do medical device companies face in today's market? Complex EHR integrations and stringent cybersecurity requirements create significant barriers to market entry. Galen Data addresses these challenges through standardized solutions and comprehensive expert support, enabling faster deployment while maintaining compliance. 3. How does Galen Data adapt its platform for different company sizes? The platform's configurable nature allows it to serve both startups and enterprise-level organizations effectively. Each implementation is tailored to address specific organizational needs while maintaining regulatory compliance and operational efficiency. 4. What factors contributed to Galen Data's successful acquisition? Detailed documentation practices and strategic relationship building proved crucial in the acquisition by Luxera Capital Partners. The company's organized approach to compliance and security documentation demonstrated significant value during the exit process. 5. What sets Galen Data apart in the medical device industry? Their commitment to genuine community engagement and customer success has fostered lasting partnerships beyond traditional business relationships. This approach has established Galen Data as a trusted partner in medical technology innovation. Learn more about Galen Data's innovative cloud platform for medical devices at galendata.com Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here.…

AWS Health Innovation Podcast

1
#118, Making Tomorrow's Treatments Available Today with Michel van Harten MD, from myTomorrows 25:49

11 weeks پیش25:49

25:49

Guy Spigelman, EMEA Healthcare and Life Sciences Startups lead at AWS, sits down with Michel van Harten MD, CEO of myTomorrows, to explore how artificial intelligence is revolutionizing clinical trial recruitment. myTomorrows is transforming the patient-trial matching process, reducing hours of manual screening to mere minutes through sophisticated AI automation - all while maintaining exceptional accuracy standards. 1. How did a practicing physician become a digital health innovator? Driven by firsthand experiences with treatment access barriers, Michel van Harten MD, transitioned from clinical practice to leading myTomorrows, combining medical expertise with technological innovation to solve healthcare delivery challenges. 2. What makes myTomorrows' platform unique in the clinical trial space? The platform leverages advanced AI to create seamless connections between patients, physicians, and clinical trials, achieving an impressive 98% accuracy rate while reducing physician screening time by over 90% . 3. How does company culture contribute to patient impact? Monthly patient speakers and mission-focused initiatives keep their 110-person team deeply connected to their purpose. This values-driven approach helps attract top talent while maintaining sustainable growth. 4. What is the global reach of myTomorrows' solution? Operating across 125 countries with 2,200+ physicians , the platform has facilitated treatment access for nearly 15,000 patients through expanded access programs and clinical trial matching. 5. How has myTomorrows evolved from startup to scale-up? Through strategic pivots and technological advancement, myTomorrows has built a sustainable growth model, positioning themselves for growth equity funding and continued market expansion. Learn more about myTomorrows at https://mytomorrows.com/ Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here.…

AWS Health Innovation Podcast

1
#117, Breaking Down Healthcare Data Silos with Mika Newton from xCures 40:26

12 weeks پیش40:26

40:26

Healthcare data fragmentation remains one of the most pressing challenges in modern medicine. In this episode, Mike Tarselli, Specialist Leader for HCLS Data & AI at AWS, explores innovative solutions with Mika Newton, CEO of xCures. Their platform is revolutionizing how healthcare organizations access and utilize patient data, transforming disconnected, and often complex medical records into actionable insights through advanced AI technology. How did xCures evolve from cancer-specific solutions to a comprehensive healthcare platform? Starting in oncology, xCures developed AI solutions to tackle complex cancer patient management. The platform's success in organizing and analyzing oncology records led to natural expansion across all medical conditions, demonstrating the universal need for better healthcare data management. What makes xCures' approach to medical record management unique? The platform leverages advanced AI and machine learning to convert fragmented medical records into structured, actionable data. This transformation enables healthcare providers to access comprehensive patient histories while maintaining strict HIPAA compliance standards. How does the AWS partnership enable xCures' scalability? By utilizing AWS infrastructure, xCures processes millions of medical records with enterprise-grade security. Their multi-tenant architecture supports rapid growth while maintaining the highest data protection standards required in healthcare. What role does AI play in improving patient record management? xCures employs sophisticated Bayesian models and natural language processing to convert complex medical documentation into searchable, meaningful data. Their semantic embedding technology provides crucial clinical context, enhancing healthcare decision-making. What is xCures' vision for the future of healthcare data access? The company aims to create internet-style healthcare interoperability, addressing critical staffing challenges while improving patient outcomes through enhanced data accessibility and integration. How are healthcare organizations implementing xCures' technology? Telehealth providers and diagnostic companies use the xCures platform to streamline patient care coordination, enabling comprehensive access to patient data during virtual consultations and diagnostic testing through their SaaS solution. Learn more about xCures at https://xcures.com/ Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here.…

AWS Health Innovation Podcast

1
#116, Programming Biology to Revolutionize Drug Discovery with Tharindi Hapuarachchi from Generate:Biomedicines 31:57

13 weeks پیش31:57

31:57

The convergence of artificial intelligence and biological engineering is ushering in a new era of drug design. On this episode of the AWS Health Innovation Podcast, Sanjit Misra speaks with Tharindi Hapuarachchi, VP of Platform Strategy & Operations at Generate:Biomedicines, about their groundbreaking work in generative biology. Through their innovative platform, they're revolutionizing how we design therapeutic proteins, bringing unprecedented speed and precision to drug development. 1. How did Tharindi's unique background prepare her for pioneering work in biotech? Her journey from mathematics to bioengineering provides the perfect blend of analytical thinking and biological understanding needed for modern therapeutic development. This interdisciplinary expertise enables her to bridge the gap between computational design and practical applications in medicine. 2. What makes Generate:Biomedicines' approach to protein design revolutionary? Their platform combines advanced machine learning with biological engineering in a novel "lab in the loop" system. This integration allows them to test millions of protein designs within weeks, dramatically accelerating the traditional drug discovery timeline. 3. How does Generate:Biomedicines maintain seamless translation from design to application? A 330-person team operates both computational models and wet labs under one roof, creating an integrated ecosystem where AI-designed proteins can be rapidly tested and validated for therapeutic use. 4. What real-world success demonstrates the platform's capabilities? Their COVID antibody development program showcases the platform's power, completing in just 17 months. The ability to simultaneously optimize multiple properties represents a significant advancement over traditional pharmaceutical development methods. 5. How does Generate:Biomedicines' infrastructure support rapid innovation? Their system combines proprietary protein databases with 24/7 automated laboratories, enabling continuous learning and iteration in the protein design process. This infrastructure creates a powerful feedback loop that enhances the platform's capabilities over time. 6. What potential impact could this technology have on healthcare accessibility? The platform aims to reduce development costs while accelerating therapeutic creation, potentially enabling more personalized treatments for underserved populations and improving access to breakthrough medicines. Learn more about Generate:Biomedicines at generatebiomedicines.com Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here.…

AWS Health Innovation Podcast

1
#115, Improving Care One Heartbeat at a Time with Dr. Jim Mault, CEO and Founder of BioIntelliSense 37:42

16 weeks پیش37:42

37:42

In a groundbreaking advancement for health monitoring, a device the size of a band-aid is transforming how we prevent medical emergencies. On this episode of the AWS Health Innovation Podcast, Yin He, Principal of Business Development for Healthcare & Life Sciences Startups, explores the future of patient care with Dr. Jim Mault, CEO and Founder of BioIntelliSense. Their conversation reveals how continuous vital sign monitoring is revolutionizing the century-old practice of patient observation. How is BioIntelliSense transforming traditional vital sign monitoring? The BioButton device captures an unprecedented 1,440 measurements daily, enabling continuous, AI-powered health monitoring. This medical-grade wearable represents a paradigm shift from periodic to constant patient observation. What makes the healthcare command center system unique? Healthcare providers can monitor up to 300 patients simultaneously through an innovative exception management system. The platform uses color-coding to transform complex data streams into actionable insights, similar to modern aviation control systems. How does continuous monitoring impact patient recovery? The system has demonstrated an impressive 80% reduction in 30-day readmissions by bridging the critical monitoring gap between hospital discharge and home recovery, providing enhanced security for both patients and their families. What role does cognitive computing play in healthcare data management? While healthcare facilities generate vast amounts of data, BioIntelliSense's cognitive computing approach processes this previously unused information into clear, actionable insights, following the successful evolution model of aviation safety systems. How does BioIntelliSense ensure successful clinical adoption? The company employs a structured three-phase implementation process, focusing on education and transformation. Healthcare facilities using the BioButton system report significant improvements in patient outcomes and reductions in unplanned transfers. What makes BioIntelliSense's approach sustainable? The company combines a subscription-based model with reusable devices to create both environmental and economic sustainability, while maintaining FDA compliance and clinical efficacy. Learn more about BioIntelliSense at www.biointellisense.com Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here.…

AWS Health Innovation Podcast

1
#114, Revolutionizing Agriculture One Seed at a Time with Ponsi Trivisvavet from Inari Agriculture 28:18

17 weeks پیش28:18

28:18

The global food system faces an unprecedented challenge: producing 50% more food by 2050 using today's available land. On the AWS Health Innovation Podcast, Yin He, Principal of Business Development for Healthcare & Life Sciences Startups, explores this critical issue with Ponsi Trivisvavet , CEO of Inari Agriculture. Learn how this innovative company is revolutionizing agriculture through AI-powered predictive design and advanced multiplex gene editing to create more efficient, sustainable crops. 1. How is Inari reimagining seed development for a sustainable future? By combining AI-powered predictive design with CRISPR technology, Inari creates resilient, high-yield crops that maximize resource efficiency. Their breakthrough approach directly addresses global food security while minimizing environmental impact. 2. What inspired the transition from electrical engineering to agricultural innovation? Ponsi Trivisvavet's background in electrical engineering evolved into a passion for agricultural transformation after witnessing technology's direct impact on farming communities. This experience fundamentally shapes Inari's mission to revolutionize crop development. 3. How does Inari overcome traditional seed development limitations? While conventional breeding faces significant constraints in annual yield improvements, Inari's advanced gene editing platform accelerates natural breeding processes, radically reducing development timelines. 4. What makes Inari's technology approach unique? The company employs a dual-technology strategy, leveraging both artificial intelligence and multiplex gene editing. Their predictive design system analyzes complex crop genomes to identify optimal genetic modifications for improved crop performance. 5. How does Inari's business model support agricultural transformation? Through strategic partnerships and royalty arrangements with existing seed companies, Inari focuses on corn, soybeans, and wheat - crops that represent 70% of global markets - to maximize their impact on food security. 6. What drives Inari's rapid growth and innovation? A culture of continuous innovation, including unique benefits and dedicated innovation leadership, has fueled Inari's expansion from 30 to over 300 employees. Their "What if?" mindset consistently challenges traditional agricultural limitations. Learn more about Inari Agriculture's innovative approach to securing our food future at inari.com Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here.…

AWS Health Innovation Podcast

1
#113, Bridging the Gap Between Medical Knowledge and Practice with Rob Brisk from Eolas Medical 45:13

18 weeks پیش45:13

45:13

Healthcare professionals access over 5 million medical references annually through Eolas Medical's platform. In this episode of the AWS Health Innovation Podcast, Alex Merwin, Head of Growth for Healthcare & Life Science Startups at AWS, sits down with Rob Brisk, Former Chief Scientific Officer of Eolas Medical. Eolas provides a digital platform that organizes medical information, helping healthcare providers quickly find answers to clinical questions at the point of care. This conversation explores the intersection of technology and healthcare, offering valuable insights into the future of medical knowledge management. How is Eolas Medical approaching AI integration in healthcare? Eolas Medical takes a cautious approach to AI integration, prioritizing safety and regulatory compliance. They balance the potential of AI with the need to maintain high standards of patient care and ethical considerations, reflecting the broader challenges in the healthcare industry. What inspired Rob Brisk's transition from cardiology to healthcare technology? Rob Brisk's journey from practicing cardiologist to tech innovator exemplifies the growing intersection of medicine and technology. His experience highlights the potential for clinicians to drive meaningful change in healthcare through digital solutions, bridging the gap between medical expertise and technological innovation. How does Eolas Medical's platform address critical needs in healthcare? The platform provides rapid access to up-to-date medical information, aligning with the industry's push towards evidence-based practice. By streamlining access to medical knowledge, Eolas supports improved efficiency in clinical decision-making and helps healthcare professionals stay current with the latest medical information. What challenges does Eolas face in building trust for their clinical AI systems? The development of Eolas Medical's RAG system highlights the complexities of introducing AI into clinical settings. Key challenges include gaining clinician acceptance, defining the role of AI in decision support, and maintaining the essential human element in healthcare while leveraging technological advancements. How does Eolas Medical's unique team composition contribute to healthcare innovation? With 70% of their engineers having medical backgrounds, Eolas Medical showcases a powerful model for healthcare innovation. This physician-engineer approach bridges the gap between clinical needs and technological solutions, potentially accelerating the development of effective digital health tools and ensuring that innovations are grounded in real-world medical practice. To learn more about Eolas Medical and their innovative platform for healthcare professionals, visit their website at https://www.eolasmedical.com/ . Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here.…

AWS Health Innovation Podcast

1
#112, Defeating the Diseases of Aging with Daniel Ives from Shift Bioscience 31:46

23 weeks پیش31:46

31:46

Imagine being able to reverse the biological clock and restore youth. That's the ambitious goal of Shift Bioscience, a biotech company pioneering novel gene-based cell rejuvenation therapies. In this episode of the AWS Health Innovation Podcast, Sanjit Misra from AWS hosts an in-depth conversation with Daniel Ives, the CEO and Founder of Shift Bioscience. Daniel's team has made significant breakthroughs in developing cell rejuvenation therapies using advanced cell simulation models and aging biomarkers to tackle the underlying driver of many age-related diseases. How did Daniel Ives' research journey lead to the founding of Shift Bioscience? Daniel's path from studying mitochondrial mutations to founding Shift Bioscience illustrates a fascinating evolution in aging research. This transition underscores the potential for AI-driven approaches to revolutionize our understanding of cellular aging and rejuvenation. What innovative approach does Shift Bioscience use to accelerate aging research? Shift Bioscience employs groundbreaking cell simulations that compress centuries of experiments into mere years. This approach enables rapid discovery of safe rejuvenation pathways, potentially fast-tracking the development of anti-aging therapies. How does Shift Bioscience position itself in the field of longevity research? Operating at the cutting edge of longevity research, Shift Bioscience focuses on fundamental aging processes. Their work challenges conventional approaches, pushing the boundaries of what's possible in cellular rejuvenation and age-related disease prevention. What is the significance of Shift Bioscience's single cell aging clock? The single cell aging clock represents a significant advancement in aging research. This machine learning-powered tool enables precise prediction of epigenetic age from single cell data, dramatically accelerating the pace of experimentation and discovery. How does Shift Bioscience address the risks associated with cell rejuvenation? Shift Bioscience has discovered novel methods to rejuvenate cells without dangerous side effects. Their approach, including a single gene intervention, avoids the pluripotency risks associated with traditional Yamanaka factors, potentially offering safer anti-aging therapies. How does cloud computing contribute to Shift Bioscience's research capabilities? By leveraging cloud computing, Shift Bioscience has revolutionized the speed and scale of aging experiments. Their ability to run hundreds of thousands of simulations in days demonstrates the power of combining biotechnology with advanced computing resources. To learn more about Shift Bioscience and their groundbreaking work in cell rejuvenation, visit their website at https://www.shiftbioscience.com/ . Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here.…

AWS Health Innovation Podcast

1
#111, Breathing New Life into Metabolic Health with Daniel Tal Mor from Lumen 27:42

24 weeks پیش27:42

27:42

Unlock the secrets of your metabolism with a single breath. On this episode of the AWS Health Innovation Podcast, Mike Tarselli, Specialist Leader for HCLS Data & AI, explores the cutting-edge world of breath-based health tech with Daniel Tal Mor, Founder & CEO of Lumen. Discover how this innovative device is transforming the way we approach metabolic health, offering real-time insights through a simple smartphone app. How does Lumen's device measure metabolism? Lumen's innovative technology measures metabolism through a single breath, providing real-time data on whether the body is burning fat or carbs. This approach democratizes metabolic health monitoring, offering an accessible alternative to expensive hospital equipment. What inspired the creation of Lumen? Lumen was born from the combined expertise of twin PhDs, Michal and Merav, who specialized in cardiac arrhythmia. Their backgrounds in nutrition and endurance athletics, coupled with frustration over limited nutrition study data, led to the development of this revolutionary metabolic measurement tool. How does the Lumen device analyze breath? The device analyzes CO2, humidity, temperature, and airflow in exhaled breath to determine metabolic state. This sophisticated technology translates complex physiological processes into actionable insights for users seeking to optimize their health. How does Lumen leverage data for personalized health recommendations? With over 66 million metabolic measurements from 300,000+ customers, Lumen offers highly personalized health recommendations. The platform's ability to provide tailored interventions based on vast datasets sets a new standard in digital health coaching. What role does cloud technology play in Lumen's functionality? Lumen's cloud-based processing enables continuous algorithm improvement and personalization without hardware changes. This approach allows the platform to adapt to various user needs, from weight loss to athletic performance optimization. How does AI contribute to Lumen's health insights? Lumen's AI analyzes diverse data points to provide context-appropriate health recommendations. The company's collaboration with AWS facilitates large-scale data storage and processing, driving continuous improvements in metabolic science. What research partnerships is Lumen involved in? Lumen is partnering with universities and hospitals to advance metabolic health research. The company's unique at-home device enables novel studies, potentially reshaping our understanding of metabolism in various populations and conditions. What does Lumen envision for the future of personalized metabolic health? Lumen anticipates a growing focus on metabolic health, partly due to weight loss medication side effects. The company's ability to detect menstrual cycle phases and menopause onset through metabolic measurements showcases the potential for highly personalized health insights. To learn more about Lumen and their innovative metabolic health technology, visit https://www.lumen.me/ . Use coupon code AWS for a special discount on a Lumen device. Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here.…

AWS Health Innovation Podcast

1
#110, Using AI to Give The Gift of Independence to Aging Adults with Nevo Elmalem from Sensi.ai 33:28

25 weeks پیش33:28

33:28

The aging population is creating unprecedented challenges in senior care. In this episode of the AWS Health Innovation Podcast, Guy Spigelman, EMEA lead for Healthcare and Life Sciences Startups at AWS, speaks with Nevo Elmalem, Co-Founder & CTO of Sensi.ai. Sensi is on a mission to unleash growth, productivity, and purpose for home care agencies, empowering every senior to safely age in place through care intelligence. Sensi.AI's sophisticated audio AI platform transforms home care by predicting and detecting care events while maintaining privacy. It equips agencies with essential insights into senior health, enabling timely interventions and tailored care plans. This reduces hospitalizations, enhances caregiver-client relationships, and prolongs service durations, allowing seniors to stay at home longer. How did personal experiences shape the founding of Sensi.ai? Nevo Elmalem's journey to founding Sensi.ai was inspired by two powerful personal experiences. These stories highlighted the critical need for holistic assessment and safety in care environments, driving the innovation behind Sensi.ai's technology. How does Sensi.ai's technology enable aging in place? Sensi.ai's audio-based monitoring system allows seniors to remain safely in their homes. Sensi's AI technology is trusted by home care agencies across the nation for its ability to identify over 100 critical insights, including early indicators of respiratory infections, UTIs, care resistance, cognitive shifts, and emergencies like falls. Our customers share how Sensi is preserving independence and quality of life for the older adults while also saving lives by enabling timely intervention. . What gives Sensi.ai a competitive edge in the eldercare market? Sensi's AI, powered by the home care industry’s largest proprietary dataset with over 1,000 years of audio data, offers unmatched precision, privacy, and comprehensiveness. Unlike traditional senior care technologies that rely on user input, Sensi operates continuously, requiring no action from seniors—an approach especially vital for emergencies and dementia care. By shifting from reactive to proactive care, Sensi enables agencies to craft personalized care plans and provide seamless support, even in caregivers' absence. This ensures consistent, tailored care for seniors while enhancing communication with families, caregivers, and healthcare providers for a holistic care experience. How did Sensi.ai approach startup challenges and funding? Nevo details Sensi.ai's lean approach to product development and funding. Their strategy of demonstrating traction before seeking VC investment proved successful, resulting in over $53 million raised to support their growth and innovation. Can you share examples of AI's impact on eldercare through Sensi.ai? Sensi benefits seniors, families, and care teams alike. It acts as a safety net by detecting medication errors, falls, cognitive decline, and predicting infections like UTIs or respiratory issues reducing hospitalizations. Additionally, it provides insights into caregiver-client dynamics for optimal match increasing caregiver retention. As a care copilot, Sensi supports home care agencies in delivering better care and driving growth. What technologies power Sensi.ai's eldercare solution? Sensi.ai leverages AWS services and combines hardware, IoT, and AI technologies. This innovative tech stack addresses the growing demand for effective, scalable eldercare solutions, positioning Sensi.ai at the forefront of the eldercare revolution. To learn more about Sensi.ai and their innovative approach to eldercare, visit their website at https://sensi.ai/ . Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here.…

AWS Health Innovation Podcast

1
#109, Transforming Real-World Data into Actionable Clinical Evidence with Dr. Brigham Hyde from Atropos Health 43:05

26 weeks پیش43:05

43:05

Transforming real-world medical data into actionable evidence in minutes, not years - this is the revolutionary approach of Atropos Health. On today's episode of the AWS Health Innovation Podcast, host Sanjit Misra has a fascinating conversation with Dr. Brigham Hyde, CEO and Co-Founder of Atropos Health. from technology developed and tested at Stanford, Atropos Health is reshaping the landscape of evidence-based medicine, providing on-demand evidence from real-world data to close critical gaps in healthcare and life sciences. Let's dive into how Atropos Health is elevating clinical outcomes, accelerating research, and driving operational efficiency. How did Atropos Health evolve from an academic project to an industry disruptor? Atropos Health's journey exemplifies the power of translating research into real-world impact. The company's mission to accelerate evidence generation aligns well with the growing demand for data-driven healthcare decision-making, showcasing how academic innovations can transform into practical solutions for the healthcare industry. What critical healthcare challenge does Atropos address? Atropos tackles the significant gap in high-quality evidence for many medical decisions. By rapidly generating real-world evidence, they aim to improve patient outcomes across diverse populations, including traditionally underrepresented groups, thus addressing a crucial need in healthcare decision-making. How does GENEVA OS™(Generative Evidence Acceleration Operating System) revolutionize healthcare research? Atropos Health’s GENEVA OS a critical infrastructure layer for the healthcare ecosystem that can rapidly, accurately, and transparently convert healthcare data into personalized evidence' streamlines complex data analysis and makes it accessible to non-technical users. This innovation significantly reduces the time and resources needed for healthcare research, potentially accelerating medical advancements and democratizing access to data-driven insights. What role does AI play in Atropos Heath's clinical insights generation? Chat RWD™, Atropos Healths' AI co-pilot, transforms clinical questions into real-world evidence studies in seconds. This technology has the potential to revolutionize point-of-care decision-making, enabling physicians to access personalized, evidence-based insights instantly, thereby enhancing the quality and efficiency of patient care. Can you provide examples of Atropos Health's real-world impact on patient care? Atropos Health's technology has demonstrated tangible benefits in clinical settings, from avoiding unnecessary tests to resolving treatment debates and improving shared decisionmaking. These case studies highlight the potential for data-driven approaches to improve healthcare efficiency and patient outcomes, showcasing the practical applications of their innovative platform. How does Atropos Health plan to expand its impact on global healthcare? I nternational expansion plans include addressing the need for diverse, representative medical evidence. By enabling global access to real-world data insights, they aim to reduce healthcare disparities and improve treatment efficacy worldwide, potentially transforming healthcare decision-making on a global scale. To learn more about how Atropos Health is revolutionizing healthcare decision-making with real-world data, visit their website at https://www.atroposhealth.com . Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here.…

AWS Health Innovation Podcast

1
#108, Accelerating Scientific Breakthroughs Through Collaborative R&D with Bogdan Knezevic from Kaleidoscope Bio 33:20

27 weeks پیش33:20

33:20

In this episode of the AWS Health Innovation Podcast, Yin He, Principal Business Development for Healthcare & Life Sciences Startups at AWS, explores the future of scientific research with Bogdan Knezevic, Co-Founder & CEO of Kaleidoscope Bio. Discover how their innovative software platform is transforming R&D by making it more collaborative, reproducible, and scalable across the life sciences industry. How is Kaleidoscope Bio revolutionizing R&D in the biotech and pharma industries? Kaleidoscope's platform streamlines R&D processes by integrating data from various sources, enhancing collaboration, and improving decision-making. This approach accelerates therapeutic development and helps companies reach clinical trials more efficiently. What role does data play in driving decisions in life sciences research? The Kaleidoscope platform aggregates critical information, allowing stakeholders to visualize and analyze data effectively. This empowers R&D leaders to make informed decisions, potentially reducing unnecessary costs and accelerating time-to-market for life-saving therapies. How does Kaleidoscope Bio cater to the diverse needs of different labs? Kaleidoscope offers customized product versions to accommodate varying technological infrastructures in life science companies. Their flexible approach ensures that both cutting-edge labs and those using basic tools can benefit from streamlined data management and improved collaboration. What design principles guide Kaleidoscope's platform development? Kaleidoscope prioritizes user-friendly interfaces to simplify complex workflows for scientists. Features like smart field mapping and one-click data highlighting demonstrate the platform's commitment to enhancing productivity in research environments. How does Kaleidoscope's platform help measure R&D efficiency and impact? The platform provides tools for assessing research productivity and identifying bottlenecks in the drug development process. This transparency enables both individual scientists and leadership to evaluate performance and optimize resource allocation. What inspired the creation of Kaleidoscope Bio? Bogdan Knezevic's background in genomics and biotech startups inspired Kaleidoscope's mission. The company's focus on solving fundamental R&D challenges reflects a deep understanding of the industry's needs and the potential for significant time and cost savings in scientific research. To learn more about Kaleidoscope Bio and their innovative R&D platform, visit kaleidoscope.bio . Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here.…

AWS Health Innovation Podcast

1
#107, Democratizing Musculoskeletal Treatment with Virtual Care, with Vijay Yanamadala from Sword Health 38:33

29 weeks پیش38:33

38:33

Suffering from chronic musculoskeletal pain? Sword Health is revolutionizing access to quality care with their cutting-edge digital therapy platform. Join Sanjit Misra, Senior Technical Product Manager at AWS, as he interviews Vijay Yanamadala, Chief Medical Officer at Sword Health, to explore how AI and virtual physical therapy are transforming the treatment landscape. 1. How is Sword Health overcoming barriers to accessing quality care? Sword Health provides tablets and mobile hotspots to ensure equitable access for all patients, regardless of location or socioeconomic status. Their platform democratizes care by reaching underserved communities and healthcare deserts. 2. How does Sword Health leverage AI to enhance physical therapy? Computer vision AI meticulously tracks patient movements during exercises, sending detailed data to physical therapists for personalized feedback and progression. This technology maximizes therapist bandwidth while ensuring optimal care. Sword Health's "Predict" AI model identifies patients at risk for unnecessary surgeries, leading to a 60% reduction in surgeries for those using their platform. This approach prioritizes conservative, evidence-based treatment. 3. How does Sword Health personalize the patient experience? Patients undergo comprehensive onboarding, including questionnaires and video calls with physical therapists to discuss goals and limitations. This personalized approach ensures tailored exercise programs from the outset. The AI assistant "Phoenix" guides patients through exercises with real-time feedback, gamification, and progress tracking, boosting engagement and adherence. Patients average 33 sessions compared to 4 for traditional in-person PT. 4. How does Sword Health measure and optimize patient outcomes? Sword Health measures patient-reported outcomes aligned with individualized goals, allowing real-time adjustments to ensure sustainable improvements in pain, disability, and work productivity. Learn more about Sword Health's innovative digital therapy platform here. Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here.…

AWS Health Innovation Podcast

1
#106, Precision Medicine for Neurodegenerative Diseases, with Brian Pepin from Rune Labs 25:28

30 weeks پیش25:28

25:28

Rune Labs is pioneering the use of real-world data to revolutionize therapy development for neurodegenerative diseases like Parkinson's. In this episode, Mike Tarselli, Specialist Leader - HCLS Data & AI at AWS, talks to Brian Pepin, CEO of Rune Labs, about the company's innovative approach to digital biomarkers and how they're working to make a difference in the lives of patients. What is Rune Labs' approach to decoding neurodegenerative diseases? Rune Labs uses real-world data to accelerate therapeutic development for neurodegenerative diseases like Parkinson's, providing access to engaged clinicians, patients, and longitudinal datasets. As precision medicine gains traction, companies like Rune Labs are well-positioned to drive innovation in this space. How are digital biomarkers revolutionizing disease tracking? Rune Labs aims to quantify subjective clinical assessments using standardized sensing and data formats, offering a more objective, repeatable, and scalable way to track disease progression and medication effects compared to traditional rating scales. This approach holds promise for neurology, which lacks quantitative biomarkers. What is StrivePD, and how does it reimagine dopamine management? StrivePD, Rune Labs' flagship product, is a dopamine care management system that automatically detects and classifies Parkinson's symptoms using the Apple Watch, providing insights to patients and clinicians for better disease management. This innovative solution reduces cognitive burden and improves access to care. How is Rune Labs empowering precision clinical trials? By leveraging data and their network, Rune Labs aims to shift the economics of phase 3 clinical trials, enabling more precise measurements and identifying better responders for promising Parkinson's drugs. Their approach could make economically viable trials for disease-modifying therapies a reality. How is Rune Labs harnessing AI for personalized care? Rune Labs utilizes machine learning on dense time series data and large language models to identify patterns predictive of medication responses, progression events, and risk factors, enabling contextualized feedback and virtual patient coaching. This multimodal approach exemplifies the potential of AI in healthcare. What advice does Brian Pepin, Rune Labs' CEO, have for founders? Brian Pepin advises founders to clearly identify and focus on one major risk at a time (scientific, clinical, or business model) and ensure early team and investors are committed to the long-term vision in healthcare, which often spans 10+ years. To learn more about Rune Labs and their innovative approach to neurodegenerative diseases, visit their website or learn more about their Parkinson’s patient app, StrivePD, by visiting www.strivepd.com . Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here.…

AWS Health Innovation Podcast

1
#105, Reducing Healthcare's $1 Trillion Admin Burden with AI, Abdel Mahmoud, Anterior 42:34

31 weeks پیش42:34

42:34

Anterior is on a mission to relieve doctors and nurses of administrative burden, starting with transforming the prior authorization process. In this episode of the AWS Health Innovation Podcast, Abdel Mahmoud, MD , CEO and Co-Founder of Anterior , shares how the company's generative AI technology is changing the game for healthcare professionals. What inspired Abdel Mahmoud's vision for Anterior? Abdel shares his journey from immigrant roots to medical school, where he realized technology's potential to improve healthcare upstream. He recounts experiences at Facebook, UCL, and Google before co-founding Anterior to reduce healthcare's $1 trillion administrative burden. How does Anterior bridge the gap between healthcare and tech? While healthcare faces resource constraints, clinicians show empathy despite challenges; tech startups prioritize rapid iteration. Anterior aligns provider and payer incentives through AI-powered clinical decisioning tools, contrasting the two worlds. How does Anterior leverage large language models? Anterior ingests unstructured clinical data, using large language models to understand medical jargon, surface insights, and increase clinician productivity reviewing cases like prior authorizations. Rigorous evaluation pipelines ensure model accuracy. What has Anterior learned about designing for seamless user experiences? A key learning has been the importance of streamlined user experiences, enabling clinicians to quickly validate AI recommendations with minimal effort, even on mobile devices. What was Anterior's fundraising journey, and what advice does Abdel offer founders? The path involved an accelerator, seed round from Sequoia, then Series A from NEA to scale. Advice includes joining accelerators, demonstrating traction, articulating an ambitious vision, and prioritizing strategic thinking as CEO. To learn more about Anterior's mission to reduce the administrative burden in healthcare, visit their website . Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here.…

AWS Health Innovation Podcast

1
#104, Decoding the Immune System with AI, Adam Laing from IMU Biosciences 29:45

32 weeks پیش29:45

29:45

On today's episode we learn all about the immune system with Adam Laing, Co-founder & Chief Scientific Officer of IMU Biosciences, as he joins Alex Merwin, Head of Growth for Healthcare & Life Science Startups at AWS, on the AWS Health Innovation Podcast. IMU Biosciences is transforming our understanding of the immune system by leveraging AI-powered immune profiling to create unprecedented insights into health and disease, to advance precision medicine through collaborations with leading pharma, research organizations, and academic institutions. 1. How is IMU Biosciences unlocking immune insights? IMU Biosciences' pioneering technology measures 80 million data points across 2,000 immune cell subsets, from a small blood sample, providing unprecedented resolution into an individual's immune profile. This enables precision medicine approaches across disease areas like cancer, autoimmunity, and cell therapy. 2. What is the potential of predictive immune profiling? By deeply characterizing immune systems, IMU aims to predict disease progression and treatment responses. Their machine learning analytics identify immune signatures that can stratify patients based on how effectively they will respond to therapies. 3. How does IMU Biosciences foster a collaborative culture? With a team spanning immunology, data science, engineering, and operations, IMU fosters a collaborative culture focused on solving complex problems. Their network and reputation helped secure early industry partnerships. 4. What is IMU Biosciences' vision for scaling precision immunology? After demonstrating their technology's potential during COVID-19 research, IMU raised a Series A to commercialize and build a predictive immune data platform. Their long-term vision is enabling preventative screening for disease risk. 5. How does IMU Biosciences leverage advances in flow cytometry? IMU leverages advances in flow cytometry instrumentation, labeling 75 markers to phenotype cells at unprecedented resolution. Robust processes ensure scalability by accounting for technical variability across samples. Learn more about IMU Biosciences here to explore their pioneering work in unlocking the complexity of the immune system and advancing precision medicine. Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here.…

AWS Health Innovation Podcast

1
#103, Revolutionizing Surgery with Physical AI, Gabriel Jones from Proprio 41:59

33 weeks پیش41:59

41:59

In this episode of the AWS Health Innovation Podcast, host Eric Zimmerman, Principal Healthcare & Life Sciences BD at AWS, sits down with Gabriel Jones, CEO of Proprio, a company revolutionizing surgery through AI, computer vision, and augmented reality. Proprio's mission is to enhance surgical precision and decision-making with real-time, interactive 3D visualization and simulations. 1. How is Proprio transforming the surgical landscape with AI? Gabriel Jones shares insights on how AI and advanced imaging will revolutionize surgery, enabling real-time data visualization and predictive analytics. This aligns with Proprio's mission to enhance surgical precision through intelligent technology. 2. What was the key to Proprio's innovative approach? The founding team's diverse expertise in neurosurgery, computer vision, and sensor systems allowed Proprio to converge disparate data sources into a novel imaging modality. This interdisciplinary approach drives innovation in surgical visualization. 3. How did Proprio navigate the product development process? While Proprio's core thesis endures, the company embraced an iterative product development cycle , learning that initial concepts require refinement through user feedback and prototyping. Constant adaptation is key in deep tech. 4. What factors have enabled Proprio's "physical AI" approach? Recent breakthroughs in AI, sensors, and data integration have created an opportune environment for Proprio's "physical AI" approach of bridging the physical and digital realms in healthcare. Timing is crucial for deep tech success. 5. How does Proprio envision democratizing healthcare innovation? Proprio envisions enabling clinicians to invent novel products and services powered by its data platform, while pressuring incumbents to accelerate innovation. This could democratize healthcare solutions development . 6. What is Proprio's focus for talent acquisition? As an AI company focused on computer vision, robotics and engineering, Proprio is actively hiring top talent to drive partnerships and growth in its transformative vision for surgery and healthcare. Learn more about Proprio and their innovative surgical technology on their website. Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here.…

AWS Health Innovation Podcast

1
#102, Decoding Human Biology with Single-Cell Insights, with Lindsay Edwards from Relation 41:03

35 weeks پیش41:03

41:03

In this episode of the AWS Health Innovation Podcast, host Yin He, Principal Business Development for Healthcare & Life Sciences Startups at AWS, sits down with Lindsay Edwards, CTO and President of Platform at Relation, a biotech company leveraging single-cell multi-omics, machine learning, and clinical insights to develop transformational medicines. 1. What is Relation's unconventional approach to drug discovery? Lindsay Edwards, a former musician turned drug hunter, embodies Relation's bold mission to transform drug discovery through multidisciplinary expertise bridging biology, data science, and creative intuition. Relation harnesses human genetic insights and single-cell data to pinpoint superior drug targets, addressing a critical bottleneck in pharmaceutical R&D. 2. How does Relation integrate lab experiments and machine learning? Relation's "Lab-in-the-Loop" approach tightly integrates wet lab experiments with machine learning, iteratively refining models that map genetic variation to disease mechanisms. Interdisciplinary collaboration between biologists, data scientists, and computational experts catalyzes this symbiosis of lab and AI. 3. How does Relation's initial focus in developing precision medicines for osteoporosis open opportunities in other therapuetic areas? By studying osteoblasts and genetic determinants of bone density, Relation aims to develop anabolic therapies driving new bone growth, addressing the large unmet need in osteoporosis with precision medicine. Their traction in osteoporosis shows how Relation can apply biological signals to improve machine learning modeling, uncover novel therapeutic targets. To learn more about Relation and their transformative approach to drug discovery, visit their website: https://www.relationrx.com/ Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here.…

AWS Health Innovation Podcast

1
#101, Improving Lab Workflows with Robotics and AI, Mostafa ElSayed of Automata 39:28

36 weeks پیش39:28

39:28

In this episode of the AWS Health Innovation Podcast, Yin He , Principal Business Development for Healthcare and Life Sciences Startups at AWS, sits down with Mostafa ElSayed , Co-founder and CEO of Automata , a company revolutionizing the way scientists work in labs by providing a full-stack solution for lab automation. How does Automata's LINQ platform streamline drug discovery workflows? Automata's LINQ platform integrates robotics, instruments, and cloud software, addressing inefficiencies in life sciences labs. As a modular "work cell", it captures structured data to accelerate collaboration and time-to-market for therapeutics. What inspired Mostafa ElSayed's vision for Automata? Mostafa ElSayed's background in architecture sparked an interest in robotics, leading him to co-found Automata and pioneer a full-stack lab automation solution. His vision fuses design principles with cutting-edge technology to transform drug R&D. What does ElSayed envision for the future of drug discovery? ElSayed envisions AI-driven drug discovery becoming the norm within a decade, with a shift towards computational "in silico" approaches over lab-based "in vitro" methods. Robust data and transparency will increase confidence in clinical candidates. How does Automata balance product vision with user feedback? Automata balances product vision with user feedback, investing heavily in hardware modularity, software UX/UI, and developer experience. Design drives customer success by optimizing different user journeys through an experience lens. To learn more about Automata and their innovative lab automation solutions, visit https://automata.tech/ . Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here.…

AWS Health Innovation Podcast

1
#100, Enabling Personalized Medicine with Virtual Biopsies, Rajarshi Banerjee from Perspectum 35:49

39 weeks پیش35:49

35:49

In this episode of the AWS Health Innovation Podcast, Amrita Sarkar, Principal Healthcare and Life Sciences Startups Business Development Manager at Amazon Web Services, sits down with Rajarshi Banerjee, aka 'Banjo', the CEO of Perspectum , a company revolutionizing the way we diagnose and monitor chronic diseases. Perspectum's medical imaging software applies artificial intelligence to enhance MRI scans, providing greater precision in measuring organ inflammation and enabling non-invasive "virtual biopsies" to avoid complications associated with invasive approaches. How did Perspectum's innovative approach to medical imaging originate? During his PhD research on cardiac MRI at Oxford, Banjo developed non-invasive tissue characterization methods. This led to creating Liver MultiScan, addressing the massive need for non-invasive liver disease diagnosis. What is Perspectum's vision for personalized medicine, and how are they working towards it? Perspectum strategically expanded beyond liver disease to conditions like long COVID, diabetes, and cancer, aligning with their vision for personalized medicine. They collaborate transparently across ethnicities and geographies to address healthcare inequities. How has Perspectum's user-friendly approach contributed to the adoption of their solutions? Perspectum designed FDA-cleared reports to effectively communicate liver disease status, replacing invasive biopsies with non-invasive LiverMultiScan in early-stage clinical trials. Their solutions influenced regulatory decisions and diagnostic criteria. How does Perspectum prioritize data security and privacy in their solutions? Meeting stringent cybersecurity standards from early collaborations with U.S. military hospitals, Perspectum emphasizes standardizing and signposting cybersecurity requirements for safe AI healthcare delivery. Their software augments physicians' capabilities while ensuring patient communication. What insights does Banjo share about fostering an entrepreneurial mindset and driving innovation? Inspired by his mother's pioneering work in computing, Banjo encourages entrepreneurs to embrace making their own mistakes. Perspectum envisions improving patient outcomes through safer procedures, faster diagnoses, and multi-organ disease analysis capabilities. In what conditions has Perspectum's non-invasive AI powered scans been shown to facilitate safer assessment and monitoring? Diabetes: Quantitative Imaging Reveals Steatosis and Fibroinflammation in Multiple Organs in People With Type 2 Diabetes: A Real-World Study Liver disease: Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosisy Liver transplant care: MRI-serum-based score accurately identifies liver transplant patients without rejection avoiding need for liver biopsy: A multisite European study Cancer: Novel multiparametric MRI detects improved future liver remnant quality post-dual vein embolization Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here.…

AWS Health Innovation Podcast

1
#99, Soothing Cries & Saving Lives with Innovative Baby Tech, Dr. Harvey Karp from Happiest Baby 31:17

40 weeks پیش31:17

31:17

In this episode of the AWS Health Innovation Podcast, Yin He , Principal Business Development for Healthcare and Life Sciences Startups at AWS, interviews Dr. Harvey Karp , Founder and CEO of Happiest Baby , the company behind the SNOO Smart Sleeper - a robotic bassinet designed to calm fussing infants and establish healthy sleep patterns. How did Dr. Karp's experience as a pediatrician lead to the creation of the SNOO? As a pediatrician and child development expert, Dr. Karp witnessed firsthand the challenges parents face with excessive infant crying and sleep deprivation. His quest to soothe colic and promote healthy sleep led him to develop the SNOO, a smart bassinet that mimics the womb environment by responding to fussing with gentle rocking and soothing sounds. What makes the SNOO a groundbreaking product in the healthcare industry? In a pioneering move, the SNOO bassinet received FDA de novo approval in March 2023 as a medical device, making it the first smart crib to achieve this status. This clearance paves the way for insurance coverage and rental programs, aligning with Karp's vision of making this technology accessible to families through employer benefits and other initiatives. What challenges did Dr. Karp face in bringing the SNOO to market? Transforming the SNOO concept into a viable product took over two years of engineering challenges to create a smooth, quiet rocking motion. Despite funding obstacles, Karp leveraged his existing brand and persevered, demonstrating the entrepreneurial perseverance required to bring innovative healthcare solutions to market. How does the SNOO challenge traditional beliefs about infant care? The SNOO raises intriguing questions about optimal infant care practices. While conventional wisdom suggests leaving babies alone is best for brain development, Karp theorizes that rocking and shushing may be neurological needs beyond just soothing techniques, challenging traditional beliefs about infant care. How has the SNOO been received by customers and healthcare professionals? With a remarkable net promoter score of 89 and use in 160 hospitals, the SNOO demonstrates extremely high customer satisfaction by reducing nurse workloads. Karp's focus on solving real family pain points is driving strong product-market fit, as evidenced by the positive reception from both parents and healthcare professionals. To learn more about Happiest Baby and the SNOO Smart Sleeper, visit http://www.happiestbaby.com/ . Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here.…

AWS Health Innovation Podcast

1
#98, Advancing Adaptive Clinical Trials with Causal ML, with Raviv Pryluk from PhaseV 37:50

41 weeks پیش37:50

37:50

In this episode of the AWS Health Innovation Podcast, Guy Spigelman, EMEA lead for Healthcare and Life Sciences Startups at Amazon Web Services, sits down with Raviv Pryluk, CEO and Co-Founder of PhaseV , a company leveraging cutting-edge technologies like reinforcement learning and causal machine learning to revolutionize clinical trial design and execution. 1. How did Raviv and his co-founder identify the clinical trials space as ripe for innovation? Raviv shares the extensive research and criteria-driven process he undertook with co-founder Elad to identify the clinical trials space as ripe for innovation. They sought an area with major positive impact potential that leveraged their expertise in machine learning, neuroscience, and engineering. 2. What innovative technologies does PhaseV employ to transform clinical trials? PhaseV's platforms harness cutting-edge technologies like reinforcement learning and causal ML to enable adaptive trial designs and advanced data analysis. This allows more efficient, ethical trials with faster detection of subgroups responding differently to treatments. 3. How does PhaseV's causal ML platform extract insights from complex biological data? PhaseV's causal ML platform can analyze intricate biological mechanisms and multi-endpoint trials to identify true causal relationships, not just correlations. This surfaces actionable insights into why certain patient subgroups respond better to specific drugs. 4. How does PhaseV aim to accelerate drug development timelines? By leveraging machine learning for surrogate endpoints and virtual head-to-head comparisons in Phase 2, PhaseV aims to predict trial outcomes faster. This could dramatically reduce the 10+ year, $3B+ timeline for new drug approvals. 5. How is PhaseV positioned to capitalize on regulatory shifts post-COVID? The pandemic prompted increasing regulatory flexibility and digitization in clinical trials. PhaseV is well-positioned to capitalize on this evolving landscape and usher in a new era of precision medicine through innovative trial methodologies. 6. How does PhaseV build its multidisciplinary team? Raviv discusses PhaseV's strategic hiring approach, carefully assembling a diverse team spanning software, data science, medicine, and biology. Maintaining an "adaptive" mindset allows continuous reevaluation based on new data. Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here.…

AWS Health Innovation Podcast

1
#97, Preventing Adverse Drug Events at Scale, with Avishai Ben-Tovim from MDI Health 36:11

42 weeks پیش36:11

36:11

Medication-related problems are a massive burden on healthcare systems, leading to adverse events, suboptimal treatments, and skyrocketing costs. MDI Health has developed an AI-driven pharmacology platform that autonomously optimizes personal medication regimens by analyzing thousands of pharmacological and patient parameters. Joining us today is Avishai Ben-Tovim , CEO and Co-Founder of MDI Health , to share how their powerful AI identifies high-risk patients, provides clinicians with evidence-based recommendations to reduce risks in real-time, and helps payers and providers execute those recommendations - ultimately reducing total care costs while improving quality. What is MDI Health's approach to Medication Therapy Mastery ? MDI Health's AI platform analyzes thousands of pharmacological and patient parameters to optimize medication regimens across populations. It identifies high-risk patients for adverse drug events and provides real-time recommendations to reduce risks and lower care costs. How did MDI Health overcome barriers in the healthcare industry? Avishai discusses how MDI Health conducted clinical studies, secured early customers through resourcefulness, and provided clinical validation to convince chief medical officers of their value proposition. What is the concept of a Collaborative AI Co-Pilot ? MDI Health's evidence-based algorithm maps pharmacological rules, trained by comparing to expert analysis on real cases. It complements existing systems by surfacing insights and suggested actions clinicians often miss. How does MDI Health aim to align healthcare incentives ? Avishai aims to enable data exchange and aligned incentives between health plans and providers. MDI Health's solution improves efficiency and holistic patient care impact for all stakeholders. What is MDI Health's approach to building a mission-driven culture ? From the start, MDI Health prioritized building a strong organizational culture focused on the mission. They foster ownership, openness, learning, and retaining employees who deeply care. How does MDI Health educate the market on their solution? MDI Health leverages conferences, relationships, and continuous improvement to educate the market on their proven AI technology and value proposition for medication optimization. Learn more about MDI Health here to understand how their AI-driven pharmacology platform can optimize medication regimens and reduce healthcare costs. Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here.…

AWS Health Innovation Podcast

1
#96, Unlocking Precision Health with Oculomics, with Carlos Ciller from Ikerian 42:01

43 weeks پیش42:01

42:01

Accelerating medical decision-making with AI is the mission of Ikerian, a Swiss software company enabling healthcare teams to harmonize and analyze data at scale. In this episode of the AWS Health Innovation Podcast, Alex Merwin , Head of Growth for Healthcare and Life Science Startups at AWS, is joined by Carlos Ciller , CEO and co-founder of Ikerian, to discuss their innovative platform and approach. Carlos shares insights into Ikerian's journey, from its origins as a retinal imaging AI startup called RetinAI, to evolving into a comprehensive data platform serving pharmaceutical companies, physicians, and researchers across therapeutic areas. The discussion explores how Ikerian is empowering stakeholders to detect diseases sooner through biomarker identification, optimize treatment decisions with curated insights, expedite clinical collaboration through efficient workflows, and accelerate drug development by aggregating learnings. Carlos also discusses the key components of their scalable cloud platform, their focus on user experience and education, and the entrepreneurial resilience required to bring such an ambitious vision to reality. Founder's Entrepreneurial Journey Carlos Ciller shares his background, from studying in Barcelona to co-founding Icarian in Switzerland. He discusses the resilience and commitment required as an entrepreneur, learning from failures, and the importance of time management after becoming a father. Oculomics: Unlocking Systemic Health The eye provides a window into systemic diseases, a field known as "oculomics." Retinal scanning offers a low-cost, automated diagnostic modality compared to alternatives like MRI, enabling early disease detection and optimized treatment decisions. Diverse Customer Needs, Unified Solution Ikerian caters to pharmaceutical companies (AI, medical, market access teams) and physicians, offering AI analysis, clinical studies, patient identification, decision support, and patient engagement through a unified, cloud-based platform. Scalable Cloud Infrastructure Enabler Leveraging Amazon's scalable cloud infrastructure, Icarian's platform can dynamically scale based on customer needs, comprising image/data management, task processing, clinical viewer, and modular AI components. User-Centric Design for Adoption Recognizing the importance of user experience and education in healthcare, Icarian focuses on user-centric design to drive platform adoption among pharmaceutical companies and physicians. Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here. To learn more about Ikerian and their innovative platform, visit ikerian.com .…

AWS Health Innovation Podcast

1
#95, Boosting Pathologist Productivity with AI, with Joseph (Yossi) Mossel from Ibex AI 34:45

44 weeks پیش34:45

34:45

In this episode of the AWS Health Innovation Podcast, we explore how Ibex AI is transforming cancer diagnosis with artificial intelligence. Host Guy Spigelman, EMEA lead for Healthcare and Life Sciences Startups at Amazon Web Services, sits down with Joseph (Yossi) Mossel, Co-Founder and CEO of Ibex AI, a pioneering company in AI-based cancer diagnostics for pathology. How did the founders of Ibex AI recognize the potential for AI in digital pathology? Yossi Mossel and Chaim Linhart had no prior healthcare experience but were driven to start a mission-driven company that could leverage Israel's strengths in tech and digitized health records. Their "aha moment" came when they learned about digital pathology scanners, leading them to apply AI to pathology diagnosis. What key milestones did Ibex AI achieve in deploying their AI solution? Ibex AI deployed its first AI algorithm for prostate cancer diagnosis at Maccabi Healthcare Services in Israel in early 2017, quickly validating its clinical impact by catching a misdiagnosis within days. Wales was the first country to nationally deploy Ibex's AI across NHS trusts for prostate and breast cancer diagnosis. How does Ibex AI prioritize seamless integration of their AI into clinical workflows? Ibex AI focuses on partnerships to integrate its AI into existing healthcare workflows and platforms, recognizing that key factors for successful healthcare AI adoption include innovation, workflow integration, and an appropriate economic model. Learn more about Ibex AI and their AI-powered cancer diagnostics platform on their website. Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here.…

به Player FM خوش آمدید!

Player FM در سراسر وب را برای یافتن پادکست های با کیفیت اسکن می کند تا همین الان لذت ببرید. این بهترین برنامه ی پادکست است که در اندروید، آیفون و وب کار می کند. ثبت نام کنید تا اشتراک های شما در بین دستگاه های مختلف همگام سازی شود.

به بیش از 500 موضوع گوش کنید

مشابه AWS Health Innovation Podcast

TERRO Ant Killer Bait Stations T300B - Liquid Bait to Eliminate Ants - 12 Count Stations for Effective Indoor Ant Control

Bounty Quick Size Paper Towels, White, 8 Family Rolls = 20 Regular Rolls (Packaging May Vary)

Zevo Flying Insect Trap & Cartridge - Plug in Fly Trap & Indoor Bug Catcher for Gnats, House & Fruit Flies - Mess-Free - Use in Any Room - Uses Blue & UV Light (1 Plug in Device & 1 Cartridge)

پادکست هایی که ارزش شنیدن دارند

AWS Health Innovation Podcast « » #104, Decoding the Immune System with AI, Adam Laing from IMU Biosciences

#104, Decoding the Immune System with AI, Adam Laing from IMU Biosciences

پادکست هایی که ارزش شنیدن دارند

به Player FM خوش آمدید!

Scott ComfortPlus Toilet Paper, 12 Double Rolls, 231 Sheets per Roll, Septic-Safe, 1-Ply Toilet Tissue

Fourth Wing (The Empyrean Book 1)

Apple AirPods Pro 2 Wireless Earbuds, Active Noise Cancellation, Hearing Aid Feature, Bluetooth Headphones, Transparency, Personalized Spatial Audio, High-Fidelity Sound, H2 Chip, USB-C Charging

Cutter Backyard Bug Control Spray Concentrate (2 Pack), Kills Mosquitoes, Fleas & Listed Ants, 32 fl Ounce

مشابه AWS Health Innovation Podcast

راهنمای مرجع سریع

AWS Health Innovation Podcast « »
#104, Decoding the Immune System with AI, Adam Laing from IMU Biosciences